

Deinove FY14 Results

Growing towards commercialisation

Business expansion increased short term losses in FY14. However the longer term prospects are more important and in FY14 Deinove made progress on both the scientific and commercial fronts. We now expect commercial revenue from 2017 and although Deinove has sufficient funds to last until Q316, we anticipate that it will seek additional funding in FY15.

Year end	Revenue (€m)	PBT* (€m)	EPS* (c)	DPS (c)	P/E (x)	Yield (%)
12/13	0.1	(5.0)	(61.5)	0.0	N/A	N/A
12/14	0.2	(6.6)	(98.6)	0.0	N/A	N/A
12/15e	0.2	(8.3)	(100.7)	0.0	N/A	N/A
12/16e	0.2	(8.5)	(91.2)	0.0	N/A	N/A

Note: *PBT and EPS are normalised, excluding intangible amortisation, exceptional items and share-based payments.

FY14 results reveal business expansion costs

FY14 net losses of €6.5m (Edison forecast loss of €6.9m) compare to net losses of €3.4m in FY13. The c €3m increase can be attributed to, an expanded cost base, reflecting a move to larger premises and additional headcount, a less favourable tax position and a non-recurring item of €0.7m, mainly relating to the aborted secondary offering (July 2014). The net cash position (as defined by Deinove) of €2.2m at FY14 has been boosted by the recent drawdown of the first tranche of the equity funding arrangement put in place with Kepler Cheuvreux (raising €2.2m in the first two months of the year) and at end February the net cash position stood at €4.1m. Further equity drawdowns, the first milestone payment from the Deinochem project (€1m) and revenue generated from providing research services to its industrial partners will allow Deinove to finance its business (cash burn c €0.6-7m per month) in FY15. The company estimates that it has sufficient financial resources to fund its current programs beyond Q316.

Significant partnership agreements signed

In FY14 Deinove achieved advances in the Deinol project, where it successfully produced a solution 9% v/v from glucose in a 20L fermenter and subsequently demonstrated the successful co-assimilation of C5 and C6 sugars. Deinove also signed important partnership agreements with blue-chip names such as Abengoa, Suez, MBI and Avril, to test its technological developments for commercial suitability. We do not expect significant commercial revenue to be generated by these agreements in FY15 and we forecast no commercial revenue from either the Deinol or the Deinochem project before 2017. In FY15 we believe that Deinove will seek further partnership agreements with blue-chip partners and that the market will expect significant milestones to be met in existing partnership agreements, particularly in relation to scaling up the technology.

Valuation: Cashflow analysis preferred approach

At a share price of c €8 and using a discount rate of 11% our cashflow analysis indicates that the market is assuming a c 35% probability of success. For our near term financing assumptions see our <u>note</u> of 2 December 2014.

Alternative energy

1 April 2015

Price	€7.75
Market cap	€43m

Net cash* (€m) at end December 2014 2.2
*Company definition

Shares in issue 5.5m
Free float 46%
Code ALDEI

Primary exchange Alternext
Secondary exchange N/A

Share price performance



Abs	(7.0)	15.0	(47.6)
Rel (local)	(8.5)	(2.4)	(54.4)
52-week high/low		€15.4	€6.0

Business description

Deinove designs, develops and markets technologies in biofuels and biochemicals by harnessing the properties of the Deinococcus bacterium.

Next events

General Assembly 6 May 2015

Analysts

Graeme Moyse +44 (0)20 3077 5700 Roger Johnston +44 (0)20 3077 5722

industrials@edisongroup.com

Edison profile page



IT & LOSS use if sales profit A ting profit (before amort. and except.) ible Amortisation tionals ting profit terest terest terest perfore tax (norm) perfore tax (FRS 3) after tax (FRS 3) ge number of shares outstanding (m) normalised (c) normalised and fully diluted (c) (IFRS) (c) nd per share (c) margin (%) thing margin (before GW and except.) (%) NCE SHEET assets ible assets ments it assets	51 0 51 (5,156)	156 0 156	IFRS 220	IFR
use If sales profit IA Iting profit (before amort. and except.) Ible Amortisation Iting profit Iterest Defore tax (norm) Defore tax (FRS 3) Indicate tax (FRS 4) Indi	0 51	0	220	
of sales profit A ting profit (before amort. and except.) ible Amortisation titionals ting profit terest before tax (norm) before tax (FRS 3) after tax (rorm.) after tax (FRS 3) ge number of shares outstanding (m) normalised (c) normalised and fully diluted (c) ((IFRS) (c) nd per share (c) margin (%) that margin (%) thing margin (before GW and except.) (%) NCE SHEET assets ible assets lie assets ments nt assets	0 51	0	220	
profit AA ting profit (before amort. and except.) ible Amortisation tionals ting profit terest before tax (norm) before tax (FRS 3) after tax (FRS 3) ge number of shares outstanding (m) normalised (c) normalised and fully diluted (c) (IFRS) (c) nd per share (c) margin (%) tax margin (%) to MA margin (before GW and except.) (%) NCE SHEET assets ible assets le assets ments int assets	51		220	22
ting profit (before amort. and except.) ible Amortisation tionals ting profit terest before tax (norm) before tax (FRS 3) after tax (FRS 3) ge number of shares outstanding (m) normalised (c) normalised and fully diluted (c) ((IFRS) (c) nd per share (c) margin (%) that margin (%) that margin (before GW and except.) (%) NCE SHEET assets ible assets le assets ments int assets		156	0	
ting profit (before amort. and except.) ible Amortisation tionals ting profit terest before tax (norm) before tax (FRS 3) after tax (FRS 3) ge number of shares outstanding (m) normalised (c) normalised and fully diluted (c) ((IFRS) (c) nd per share (c) margin (%) that margin (%) that margin (before GW and except.) (%) NCE SHEET assets ible assets le assets ments int assets	(5.156)	100	220	22
ible Amortisation tionals ting profit terest before tax (norm) before tax (FRS 3) after tax (norm.) after tax (FRS 3) ge number of shares outstanding (m) normalised (c) normalised and fully diluted (c) (IFRS) (c) nd per share (c) margin (%) the margin (%) thing margin (before GW and except.) (%) NCE SHEET assets ible assets le assets ments nt assets	(0,100)	(6,515)	(7,467)	(7,567
ible Amortisation tionals ting profit terest before tax (norm) before tax (FRS 3) after tax (norm.) after tax (FRS 3) ge number of shares outstanding (m) normalised (c) normalised and fully diluted (c) (IFRS) (c) nd per share (c) margin (%) the margin (%) thing margin (before GW and except.) (%) NCE SHEET assets ible assets le assets ments nt assets	(5,156)	(6,520)	(8,253)	(8,504
ting profit terest before tax (norm) before tax (FRS 3) after tax (norm.) after tax (FRS 3) ge number of shares outstanding (m) normalised (c) normalised and fully diluted (c) (IFRS) (c) nd per share (c) margin (%) the margin (%) ting margin (before GW and except.) (%) NCE SHEET assets lee assets lee assets ments nt assets	367	540	26	2
ting profit terest Defore tax (norm) Defore tax (FRS 3) after tax (FRS 3) after tax (FRS 3) ge number of shares outstanding (m) normalised (c) normalised and fully diluted (c) (IFRS) (c) nd per share (c) margin (%) VA margin (%) NCE SHEET The sassets The	21	(735)	0	
terest Defore tax (norm) Defore tax (FRS 3) after tax (FRS 3) after tax (FRS 3) ge number of shares outstanding (m) normalised (c) normalised and fully diluted (c) (IFRS) (c) nd per share (c) margin (%) NA margin (%) ting margin (before GW and except.) (%) NCE SHEET assets ble assets ments nt assets	0	Ó	0	
terest Defore tax (norm) Defore tax (FRS 3) after tax (FRS 3) after tax (FRS 3) ge number of shares outstanding (m) normalised (c) normalised and fully diluted (c) (IFRS) (c) nd per share (c) margin (%) NA margin (%) ting margin (before GW and except.) (%) NCE SHEET assets ble assets ments nt assets	(4,768)	(6,715)	(8,227)	(8,47
perfore tax (norm) perfore tax (FRS 3) after tax (norm.) after tax (FRS 3) ge number of shares outstanding (m) normalised (c) normalised and fully diluted (c) (IFRS) (c) nd per share (c) margin (%) Ah margin (%) ting margin (before GW and except.) (%) NCE SHEET assets ible assets lee assets ments nt assets	122	(37)	(12)	(-)
perfore tax (FRS 3) after tax (norm.) after tax (FRS 3) ge number of shares outstanding (m) normalised (c) normalised and fully diluted (c) (IFRS) (c) nd per share (c) margin (%) that margin (%) thing margin (before GW and except.) (%) NCE SHEET assets ible assets le assets ments nt assets	(5,034)	(6,557)	(8,265)	(8,503
after tax (norm.) after tax (FRS 3) ge number of shares outstanding (m) normalised (c) normalised and fully diluted (c) (IFRS) (c) nd per share (c) margin (%) that margin (before GW and except.) (%) NCE SHEET assets ible assets le assets ments nt assets	(5,380)	(7,832)	(8,291)	(8,529
after tax (FRS 3) ge number of shares outstanding (m) normalised (c) normalised and fully diluted (c) (IFRS) (c) nd per share (c) margin (%) NA margin (%) ting margin (before GW and except.) (%) NCE SHEET assets ible assets ible assets ments nt assets	1,960	1,374	2,148	2,19
after tax (FRS 3) ge number of shares outstanding (m) normalised (c) normalised and fully diluted (c) (IFRS) (c) nd per share (c) margin (%) NA margin (%) ting margin (before GW and except.) (%) NCE SHEET assets ible assets ible assets ments nt assets	(3,074)	(5,183)	(6,117)	(6,311
ge number of shares outstanding (m) normalised (c) normalised and fully diluted (c) (IFRS) (c) nd per share (c) margin (%) NA margin (%) ting margin (before GW and except.) (%) NCE SHEET assets ible assets ble assets ments nt assets	(3,420)	(6,458)	(6,143)	(6,338
normalised (c) normalised and fully diluted (c) (IFRS) (c) nd per share (c) margin (%) th margin (%) ting margin (before GW and except.) (%) NCE SHEET assets ible assets le assets ments nt assets			, ,	
normalised and fully diluted (c) (IFRS) (c) nd per share (c) margin (%) A margin (%) ting margin (before GW and except.) (%) NCE SHEET assets ible assets ble assets ments nt assets	5.0 (61.5)	5.3 (98.6)	6.1 (100.7)	6. (91.2
(IFRS) (c) nd per share (c) margin (%) NA margin (%) ting margin (before GW and except.) (%) NCE SHEET assets ible assets ple assets ments nt assets				
nd per share (c) margin (%) tA margin (%) ting margin (before GW and except.) (%) NCE SHEET assets ible assets ple assets ments nt assets	(48.7)	(78.8)	(82.8)	(76.6
margin (%) A margin (%) ting margin (before GW and except.) (%) NCE SHEET assets ible assets ple assets ments at assets	(53.7)	(102.3)	(100.3)	(90.8
A margin (%) ting margin (before GW and except.) (%) NCE SHEET assets ible assets ole assets ments nt assets	0.0	0.0	0.0	0.
ting margin (before GW and except.) (%) NCE SHEET assets ible assets ple assets ments at assets	100.0	100.0	N/A	N/
NCE SHEET assets ible assets ele assets ments at assets	N/A	N/A	N/A	N/A
assets ible assets ele assets ments nt assets	N/A	N/A	N/A	N/A
assets ible assets ele assets ments nt assets				
ele assets ments nt assets	2,832	2,303	2,093	1,73
ele assets ments nt assets	85	99	73	4
ments nt assets	608	1,407	1,221	88
nt assets	2,139	797	799	79
	4,128	4,650	6,318	5,67
	0	0	0	-,
rs	2,188	2,110	1,665	1,77
·	1,872	966	4,329	3,57
	68	1,574	324	32
nt liabilities	(1,305)	(2,203)	(1,441)	(1,556
DIS	(1,245)	(1,441)	(1,441)	(1,441
term borrowings	(60)	(762)	0	(115
erm liabilities	(3,061)	(4,546)	(5,544)	(7,544
erm borrowings	(3,057)	(4,550)	(5,550)	(7,550
long-term liabilities	(4)	4	6	(1,000
sets	2,594	204	1,425	(1,692
FLOW	2,00.		.,.20	(1,002
	/F 400\	(0.400)	(7,000)	/7.C75
ting cash flow	(5,492) 122	(8,460)	(7,022)	(7,677
terest		(37)	(12)	0.40
	1,960	1,374	2,148	2,19
((375)	(1,338)	(600)	(600
sitions/disposals	3,779	1,307	0	2.00
cing	766	4,053	8,610	3,22
nds	0	0	0	(0.00
sh flow	760	(3,101)	3,125	(2,865
ng net debt/(cash)	2,005	1,245	4,346	1,22
ance leases initiated	0	0	0	
	0	0	0	
g net debt/(cash)	1,245	4,346	1,221	4,08

Source: Edison Investment Research. Note: Deinove includes fixed-asset investments (corporate bonds) as part of its net debt/cash calculation. The acquisition of the bonds is shown in the acquisition/disposal line of the cash flow statement. Long-term borrowings (conditional advances) are not included in Deinove's net debt calculation.

Deinove | 1 April 2015



Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/regulater/firm/BasicDetails.do?sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. NZ is registered on the New Zealand Financial Sevice Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Intel (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAIMER

Copyright 2015 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Deinove and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed any anamer whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed as a Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "holesales clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as describe